EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development

Stephen Boulton, Mathieu J F Crupi, Siddharth Singh, Madalina E Carter-Timofte, Taha Azad, Bailey C Organ, Xiaohong He, Rida Gill, Serge Neault, Taylor Jamieson, Jaahnavi Dave, Naziia Kurmasheva und 10 weitere

Journal of Biological Chemistry · 2023

DOI: 10.1016/j.jbc.2023.104749 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Stephen Boulton und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Biochemistry, Microbiology and Immunology, Un…. Hauptthemen laut MEDLINE: Antiviral Agents, COVID-19, Mpox, Monkeypox, Vaccinia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research, Hartmann Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent SARS-CoV-2 and mpox outbreaks have highlighted the need to expand our arsenal of broad-spectrum antiviral agents for future pandemic preparedness. Host-directed antivirals are an important tool to accomplish this as they typically offer protection against a broader range of viruses than direct-acting antivirals and have a lower susceptibility to viral mutations that cause drug resistance. In this study, we investigate the exchange protein activated by cAMP (EPAC) as a target for broad-spectrum antiviral therapy. We find that the EPAC-selective inhibitor, ESI-09, provides robust protection against a variety of viruses, including SARS-CoV-2 and Vaccinia (VACV)-an orthopox virus from the same family as mpox. We show, using a series of immunofluorescence experiments, that ESI-09 remodels the actin cytoskeleton through Rac1/Cdc42 GTPases and the Arp2/3 complex, impairing internalization of viruses that use clathrin-mediated endocytosis (e.g. VSV) or micropinocytosis (e.g. VACV). Additionally, we find that ESI-09 disrupts syncytia formation and inhibits cell-to-cell transmission of viruses such as measles and VACV. When administered to immune-deficient mice in an intranasal challenge model, ESI-09 protects mice from lethal doses of VACV and prevents formation of pox lesions. Altogether, our finding shows that EPAC antagonists such as ESI-09 are promising candidates for broad-spectrum antiviral therapy that can aid in the fight against ongoing and future viral outbreaks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCOVID-19Mpox, MonkeypoxVacciniaAnimalsMiceSARS-CoV-2Vaccinia virusHydrazonesIsoxazoles

Stichwörter der Autor:innen

COVID-19EPACESI-09HSV-1Rho GTPasesSARS-CoV-2VSVactinadenovirusantiviralmeaslesmpoxvaccinia

Substanzen

Antiviral Agents3-(5-tert-butylisoxazol-3-yl)-2-((3-chlorophenyl)hydrazono)-3-oxopropionitrileHydrazonesIsoxazoles

Autor:innen und Institutionen

  • Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada. Electronic address: sboul…
  • Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.
  • Aarhus University, Department of Biomedicine, Aarhus C, Denmark.
  • Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada; Faculty of Medicine and H…
  • Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
  • Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada; Public Health Agency of C…

Förderung

  • CIHR
  • Canadian Institutes of Health Research
  • Hartmann Fonden
  • Natural Sciences and Engineering Research Council of Canada
  • Ottawa Hospital Foundation
  • Canadian Cancer Society
  • Lundbeck Foundation
  • Kræftens Bekæmpelse

Zitieren

APA

Boulton, S., Crupi, M. J. F., Singh, S., Carter-Timofte, M. E., Azad, T., Organ, B. C., He, X., Gill, R., Neault, S., Jamieson, T., Dave, J., Kurmasheva, N., Austin, B., Petryk, J., Singaravelu, R., Huang, B. Z., Franco, N., Babu, K., Parks, R. J., …, & Bell, J. C. (2023). Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.104749

Vancouver

Boulton S, Crupi MJF, Singh S, Carter-Timofte ME, Azad T, Organ BC, et al. Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.104749

BibTeX
@article{Boulton2023,
  author = {Boulton, Stephen and Crupi, Mathieu J F and Singh, Siddharth and Carter-Timofte, Madalina E and Azad, Taha and Organ, Bailey C and He, Xiaohong and Gill, Rida and Neault, Serge and Jamieson, Taylor and Dave, Jaahnavi and Kurmasheva, Naziia and Austin, Bradley and Petryk, Julia and Singaravelu, Ragunath and Huang, Ben Zhen and Franco, Noah and Babu, Kaaviya and Parks, Robin J and Ilkow, Carolina S and Olagnier, David and Bell, John C},
  title = {Inhibition of exchange proteins directly activated by cAMP as a strategy for broad-spectrum antiviral development},
  journal = {Journal of Biological Chemistry},
  year = {2023},
  doi = {10.1016/j.jbc.2023.104749}
}
Kostenlos starten →